Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)-Reference-Cited by-同舟云学术

Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)

Published:2024-08-09 Issue: Volume: Page:1-16
ISSN:0360-2532
Container-title:Drug Metabolism Reviews
language:en
Short-container-title:Drug Metabolism Reviews

Author:

Zhu Lulin¹,Yang Xinxin²,Wu Shanshan²,Dong Rong¹,Yan Youyou¹,Lin Nengming¹²³⁴,Zhang Bo¹²³⁴,Tan Biqin¹²

Affiliation:

1. Department of Pharmacy, Key Laboratory of Clinical CancerPharmacology andToxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China

2. School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China

3. Westlake Laboratory of Life Sciences and Biomedicine of Zhejiang Province, Hangzhou, China

4. Cancer Center, Zhejiang University, Hangzhou, China

Funder

National Natural Science Foundation of China

Huadong Medicine　Joint Funds of the Zhejiang Provincial Natural Science Foundation of China

Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents

Zhejiang Provincial Medical and Health Technology Project

Hangzhou bio-medicine and health industry development support science and technology

Hospital Pharmaceutical Research Fund Project of Zhejiang Provincial Pharmaceutical Association

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03602532.2024.2388203

Reference129 articles.

1. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors

2. EGFR TKI combination with immunotherapy in non-small cell lung cancer

3. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

4. Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model

5. Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity